Immunity, immunopathology, and human vaccine development against sexually transmitted Chlamydia trachomatis

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 9, 2014, Pages 2664-2673

  Rey Ladino, Jose ^a,b   Ross, Allen G P ^c   Cripps, Allan W ^c  

^a ALFAISAL UNIVERSITY   (Saudi Arabia)

^b KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^c GRIFFITH UNIVERSITY   (Australia)

Author keywords

Chlamydia trachomatis; Dendritic cells; Immunity; Pathology; Vaccine

Indexed keywords

BACTERIAL VACCINE; CHLAMYDIA TRACHOMATIS VACCINE; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIGEN RECOGNITION; ARTICLE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CELLULAR IMMUNITY; CHLAMYDIASIS; DENDRITIC CELL; DISEASE DURATION; DISEASE SEVERITY; EFFECTOR CELL; HUMAN; IMMUNITY; IMMUNOPATHOLOGY; INNATE IMMUNITY; MOLECULAR RECOGNITION; NONHUMAN; SEXUALLY TRANSMITTED DISEASE; TH1 CELL; VACCINATION; VACCINE PRODUCTION; ANIMAL; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; DISEASE MODEL; DRUG DEVELOPMENT; GENITAL TRACT INFECTION; IMMUNOLOGY; INCIDENCE; ISOLATION AND PURIFICATION; MEDICAL RESEARCH; MONONUCLEAR CELL; PATHOLOGY; SECRETION (PROCESS); SEXUALLY TRANSMITTED DISEASES, BACTERIAL; TRENDS;

ANIMALS; BACTERIAL VACCINES; BIOMEDICAL RESEARCH; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; HUMANS; INCIDENCE; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; REPRODUCTIVE TRACT INFECTIONS; SEXUALLY TRANSMITTED DISEASES, BACTERIAL; TH1 CELLS;

EID: 84920145467     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.29683     Document Type: Article

References (124)

1. Belland R, Ojcius DM, Byrne GI. Chlamydia. Nat Rev Microbiol 2004; 2:530-1; PMID:15248311; http://dx.doi.org/10.1038/nrmicro931
2. World Health Organization. Global Prevalence and Incidence of Selected Curable Sexually Transmitted Infections: Overview and Estimates [Internet]. Geneva: World Health Organization; 2001 [cited 2012 Aug 8]. Available from: http://www.who.int/hiv/pub/sti/who-hiv-aids-2001.02.pdf
3. Peipert JF. Clinical practice. Genital chlamydial infections. N Engl J Med 2003; 349:2424-30; PMID:14681509; http://dx.doi.org/10.1056/NEJMcp030542
4. Brunham RC, Rey-Ladino J. Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine. Nat Rev Immunol 2005; 5:149-61; PMID:15688042; http://dx.doi.org/10.1038/nri1551
5. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2009 [Internet]. Atlanta, US: Division of preventive STD prevention, Department of Health and Human Services, CDCP; 2010 [cited 2012 Aug 12]. Available from: http://www.cdc.gov/std/stats09/surv2009-Complete.pdf
6. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 1993 [Internet]. Atlanta, US: Division of preventive STD prevention, Department of Health and Human Services, CDCP; 1994 [cited 2012 Sept 1]. Available from: http:// wonder.cdc.gov/wonder/STD/OSTD3009.PCW. html
7. Brunham RC, Pourbohloul B, Mak S, White R, Rekart ML. The unexpected impact of a Chlamydia trachomatis infection control program on susceptibility to reinfection. J Infect Dis 2005; 192:1836-44; PMID:16235186; http://dx.doi.org/10.1086/497341
8. Low N. Screening programmes for chlamydial infection: when will we ever learn? BMJ 2007; 334:725-8; PMID:17413173; http://dx.doi.org/10.1136/bmj.39154.378079.BE
9. Fenton KA, Lowndes CM. Recent trends in the epidemiology of sexually transmitted infections in the European Union. Sex Transm Infect 2004; 80: 255-63; PMID:15295121; http://dx.doi.org/10.1136/sti.2004.009415
10. Parrish DD, Kent CK. Access to care issues for African American communities: implications for STD disparities. Sex Transm Dis 2008; 35(Suppl):S19-22; PMID:18946368; http://dx.doi.org/10.1097/OLQ.0b013e31818f2ae1
11. Hvid M, Baczynska A, Deleuran B, Fedder J, Knudsen HJ, Christiansen G, Birkelund S. Interleukin-1 is the initiator of Fallopian tube destruction during Chlamydia trachomatis infection. Cell Microbiol 2007; 9:2795-803; PMID:17614966; http://dx.doi.org/10.1111/j.1462-5822.2007.00996.x
12. Igietseme JU, He Q, Joseph K, Eko FO, Lyn D, Ananaba G, Campbell A, Bandea C, Black CM. Role of T lymphocytes in the pathogenesis of Chlamydia disease. J Infect Dis 2009; 200:926-34; PMID:19656067; http://dx.doi.org/10.1086/605411
13. Van Voorhis WC, Barrett LK, Sweeney YT, Kuo CC, Patton DL. Repeated Chlamydia trachomatis infection of Macaca nemestrina fallopian tubes produces a Th1-like cytokine response associated with fibrosis and scarring. Infect Immun 1997; 65:2175-82; PMID:9169748
14. Gottlieb SL, Martin DH, Xu F, Byrne GI, Brunham RC. Summary: The natural history and immunobiology of Chlamydia trachomatis genital infection and implications for Chlamydia control. J Infect Dis 2010; 201(Suppl 2):S190-204; PMID:20524236; http://dx.doi.org/10.1086/652401
15. Darville T, Hiltke TJ. Pathogenesis of genital tract disease due to Chlamydia trachomatis. J Infect Dis 2010; 201(Suppl 2):S114-25; PMID:20524234; http://dx.doi.org/10.1086/652397
16. Boscardin SB, Hafalla JC, Masilamani RF, Kamphorst AO, Zebroski HA, Rai U, Morrot A, Zavala F, Steinman RM, Nussenzweig RS, et al. Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses. J Exp Med 2006; 203:599-606; PMID:16505139; http://dx.doi.org/10.1084/jem.20051639
17. Barron AL, Rank RG, Moses EB. Immune response in mice infected in the genital tract with mouse pneumonitis agent (Chlamydia trachomatis biovar). Infect Immun 1984; 44:82-5; PMID:6706408
18. Rank RG, Whittum-Hudson JA. Protective immunity to chlamydial genital infection: evidence from animal studies. J Infect Dis 2010; 201(Suppl 2):S168-77; PMID:20470052; http://dx.doi.org/10.1086/652399
19. Molano M, Meijer CJ, Weiderpass E, Arslan A, Posso H, Franceschi S, Ronderos M, M͡noz N, van den Brule AJ. The natural course of Chlamydia trachomatis infection in asymptomatic Colombian women: a 5-year follow-up study. J Infect Dis 2005; 191:907-16; PMID:15717266; http://dx.doi.org/10.1086/428287
20. Ramsey KH, Newhall WJ 5th, Rank RG. Humoral immune response to chlamydial genital infection of mice with the agent of mouse pneumonitis. Infect Immun 1989; 57:2441-6; PMID:2744854
21. Punnonen R, Terho P, Nikkanen V, Meurman O. Chlamydial serology in infertile women by immunofluorescence. Fertil Steril 1979; 31:656-9; PMID:376359
22. Witkin SS, Jeremias J, Neuer A, David S, Kligman I, Toth M, Willner E, Witkin K. Immune recognition of the 60kD heat shock protein: implications for subsequent fertility. Infect Dis Obstet Gynecol 1996; 4:152-8; PMID:18476087; http://dx.doi.org/10.1155/S1064744996000336
23. Ramsey KH, Soderberg LS, Rank RG. Resolution of chlamydial genital infection in B-cell-deficient mice and immunity to reinfection. Infect Immun 1988; 56:1320-5; PMID:3258586
24. Morrison SG, Morrison RP. Resolution of secondary Chlamydia trachomatis genital tract infection in immune mice with depletion of both CD4 Cand CD8C T cells. Infect Immun 2001; 69:2643-9; PMID:11254630; http://dx.doi.org/10.1128/ IAI.69.4.2643-2649.2001
25. Su H, Caldwell HD. CD4C T cells play a significant role in adoptive immunity to Chlamydia trachomatis infection of the mouse genital tract. Infect Immun 1995; 63:3302-8; PMID:7642259
26. Wang S, Fan Y, Brunham RC, Yang X. IFN-γamma knockout mice show Th2-associated delayed-type hypersensitivity and the inflammatory cells fail to localize and control chlamydial infection. Eur J Immunol 1999; 29:3782-92; PMID:10556835; http://dx.doi.org/10.1002/(SICI)1521-4141(199911)29:11≤3782::AID-IMMU3782≥3.0.CO;2-B
27. Hawkins RA, Rank RG, Kelly KA. A Chlamydia tra-chomatis-specific Th2 clone does not provide protection against a genital infection and displays reduced trafficking to the infected genital mucosa. Infect Immun 2002; 70:5132-9; PMID:12183563; http://dx.doi.org/10.1128/IAI.70.9.5132-5139.2002
28. Gondek DC, Olive AJ, Stary G, Starnbach MN. CD4 C T cells are necessary and sufficient to confer protection against Chlamydia trachomatis infection in the murine upper genital tract. J Immunol 2012; 189:2441-9; PMID:22855710; http://dx.doi.org/10.4049/jimmunol.1103032
29. Rank RG, Bowlin AK, Kelly KA. Characterization of lymphocyte response in the female genital tract during ascending Chlamydial genital infection in the guinea pig model. Infect Immun 2000; 68:5293-8; PMID:10948157; http://dx.doi.org/10.1128/IAI.68.9.5293-5298.2000
30. Van Voorhis WC, Barrett LK, Sweeney YT, Kuo CC, Patton DL. Analysis of lymphocyte phenotype and cytokine activity in the inflammatory infiltrates of the upper genital tract of female macaques infected with Chlamydia trachomatis. J Infect Dis 1996; 174: 647-50; PMID:8769630; http://dx.doi.org/10.1093/infdis/174.3.647
31. Ficarra M, Ibana JS, Poretta C, Ma L, Myers L, Taylor SN, Greene S, Smith B, Hagensee M, Martin DH, et al. A distinct cellular profile is seen in the human endocervix during Chlamydia trachomatis infection. Am J Reprod Immunol 2008; 60:415-25; PMID:18798835; http://dx.doi.org/10.1111/j.1600-0897.2008.00639.x
32. Beatty WL, Belanger TA, Desai AA, Morrison RP, Byrne GI. Tryptophan depletion as a mechanism of gamma interferon-mediated chlamydial persistence. Infect Immun 1994; 62:3705-11; PMID:8063385
33. Taylor MW, Feng GS. Relationship between inter-feron-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J 1991; 5:2516-22; PMID:1907934
34. Roms̈anik M, Martirosian G, Wojciechowska-Wieja A, Cielik K, Kaź mierczak W. [Co-occurence of indolproducing bacterial strains in the vagina of women infected with Chlamydia trachomatis]. Ginekol Pol 2007; 78:611-5; PMID:18050609
35. Roshick C, Wood H, Caldwell HD, McClarty G. Comparison of gamma interferon-mediated antichlamydial defense mechanisms in human and mouse cells. Infect Immun 2006; 74:225-38; PMID:16368976; http://dx.doi.org/10.1128/IAI.74.1.225-238.2006
36. Ramsey KH, Sigar IM, Rana SV, Gupta J, Holland SM, Byrne GI. Role for inducible nitric oxide synthase in protection from chronic Chlamydia trachomatis urogenital disease in mice and its regulation by oxygen free radicals. Infect Immun 2001; 69:7374-9; PMID:11705910; http://dx.doi.org/10.1128/IAI.69.12.7374-7379.2001
37. Nelson DE, Virok DP, Wood H, Roshick C, Johnson RM, Whitmire WM, Crane DD, Steele-Mortimer O, Kari L, McClarty G, et al. Chlamydial IFN-gamma immune evasion is linked to host infection tropism. Proc Natl Acad Sci U S A 2005; 102:10658-63; PMID:16020528; http://dx.doi.org/10.1073/pnas.0504198102
38. Jayarapu K, Kerr M, Ofner S, Johnson RM. Chlamydia-specific CD4 T cell clones control Chlamydia muridarum replication in epithelial cells by nitric oxide-dependent and -independent mechanisms. J Immunol 2010; 185:6911-20; PMID:21037093; http://dx.doi.org/10.4049/jimmunol.1002596
39. Rank RG, Batteiger BE, Soderberg LS. Susceptibility to reinfection after a primary chlamydial genital infection. Infect Immun 1988; 56:2243-9; PMID:2457553
40. Geisler WM. Duration of untreated, uncomplicated Chlamydia trachomatis genital infection and factors associated with chlamydia resolution: a review of human studies. J Infect Dis 2010; 201(Suppl 2): S104-13; PMID:20470048; http://dx.doi.org/10.1086/652402
41. Morré SA, van den Brule AJ, Rozendaal L, Boeke AJ, Voorhorst FJ, de Blok S, Meijer CJ. The natural course of asymptomatic Chlamydia trachomatis infections: 45% clearance and no development of clinical PID after one-year follow-up. Int J STD AIDS 2002; 13(Suppl 2):12-8; PMID:12537719; http://dx.doi. org/10.1258/095646202762226092
42. Ingalls RR, Rice PA, Qureshi N, Takayama K, Lin JS, Golenbock DT. The inflammatory cytokine response to Chlamydia trachomatis infection is endotoxin mediated. Infect Immun 1995; 63:3125-30; PMID:7542638
43. Brunham RC, Plummer FA, Stephens RS. Bacterial antigenic variation, host immune response, and patho-gen-host coevolution. Infect Immun 1993; 61: 2273-6; PMID:8500868
44. Beatty WL, Morrison RP, Byrne GI. Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis. Microbiol Rev 1994; 58:686-99; PMID:7854252
45. Belland RJ, Nelson DE, Virok D, Crane DD, Hogan D, Sturdevant D, Beatty WL, Caldwell HD. Transcriptome analysis of chlamydial growth during IFN-gamma-mediated persistence and reactivation. Proc Natl Acad Sci U S A 2003; 100:15971-6; PMID:14673075; http://dx.doi.org/10.1073/pnas.2535394100
46. Beatty WL, Byrne GI, Morrison RP. Repeated and persistent infection with Chlamydia and the development of chronic inflammation and disease. Trends Microbiol 1994; 2:94-8; PMID:8156277; http://dx.doi.org/10.1016/0966-842X(94)90542-8
47. Zhong G, Liu L, Fan T, Fan P, Ji H. Degradation of transcription factor RFX5 during the inhibition of both constitutive and interferon gamma-inducible major histocompatibility complex class I expression in chlamydia-infected cells. J Exp Med 2000; 191:1525-34; PMID:10790427; http://dx.doi.org/10.1084/jem.191.9.1525
48. Datta SD, Sternberg M, Johnson RE, Berman S, Papp JR, McQuillan G, Weinstock H. Gonorrhea and chlamydia in the United States among persons 14 to 39 years of age, 1999 to 2002. Ann Intern Med 2007; 147:89-96; PMID:17638719; http://dx.doi.org/10.7326/0003-4819-147-2-200707170-00007
49. Kimani J, Maclean IW, Bwayo JJ, MacDonald K, Oyugi J, Maitha GM, Peeling RW, Cheang M, Nagelkerke NJ, Plummer FA, et al. Risk factors for Chlamydia trachomatis pelvic inflammatory disease among sex workers in Nairobi, Kenya. J Infect Dis 1996; 173:1437-44; PMID:8648217; http://dx.doi. org/10.1093/infdis/173.6.1437
50. Brunham RC, Kimani J, Bwayo J, Maitha G, Maclean I, Yang C, Shen C, Roman S, Nagelkerke NJ, Cheang M, et al. The epidemiology of Chlamydia trachomatis within a sexually transmitted diseases core group. J Infect Dis 1996; 173:950-6; PMID:8603976; http://dx.doi.org/10.1093/infdis/173.4.950
51. Cohen CR, Koochesfahani KM, Meier AS, Shen C, Karunakaran K, Ondondo B, Kinyari T, Mugo NR, Nguti R, Brunham RC. Immunoepidemiologic profile of Chlamydia trachomatis infection: importance of heat-shock protein 60 and interferon- gamma. J Infect Dis 2005; 192:591-9; PMID:16028127; http://dx.doi.org/10.1086/432070
52. Vicetti Miguel RD, Harvey SA, LaFramboise WA, Reighard SD, Matthews DB, Cherpes TL. Human female genital tract infection by the obligate intracellular bacterium Chlamydia trachomatis elicits robust Type 2 immunity. PLoS One 2013; 8:e58565; PMID:23555586; http://dx.doi.org/10.1371/journal.pone.0058565
53. Rasmussen SJ, Eckmann L, Quayle AJ, Shen L, Zhang YX, Anderson DJ, Fierer J, Stephens RS, Kagnoff MF. Secretion of proinflammatory cytokines by epithelial cells in response to Chlamydia infection suggests a central role for epithelial cells in chlamydial pathogenesis. J Clin Invest 1997; 99:77-87; PMID:9011579; http://dx.doi.org/10.1172/JCI119136
54. Ault KA, Tawfik OW, Smith-King MM, Gunter J, Terranova PF. Tumor necrosis factor-alpha response to infection with Chlamydia trachomatis in human fallopian tube organ culture. Am J Obstet Gynecol 1996; 175:1242-5; PMID:8942495; http://dx.doi.org/10.1016/S0002-9378(96)70035-2
55. Agrawal T, Vats V, Salhan S, Mittal A. Determination of chlamydial load and immune parameters in asymptomatic, symptomatic and infertile women. FEMS Immunol Med Microbiol 2009; 55:250-7; PMID:19159426; http://dx.doi.org/10.1111/j.1574-695X.2008.00530.x
56. Darville T, O'Neill JM, Andrews CW Jr.,Nagarajan UM, Stahl L, Ojcius DM. Toll-like receptor-2, but not Tolllike receptor-4, is essential for development of oviduct pathology in chlamydial genital tract infection. J Immunol 2003; 171:6187-97; PMID:14634135; http://dx.doi.org/10.4049/jimmunol.171.11.6187
57. O'Connell CM, Ingalls RR, Andrews CW Jr., Scurlock AM, Darville T. Plasmid-deficient Chlamydia muridarum fail to induce immune pathology and protect against oviduct disease. J Immunol 2007; 179:4027-34; PMID:17785841; http://dx.doi.org/10.4049/jimmunol.179.6.4027
58. Dong X, Liu Y, Chang X, et al. Signaling via TNFR1 but not TLR2 contributes significantly to hydrosalpinx development following Chlamydiamuridaruminfection. Infect Immun 2014; 82:1833-9; PMID:24549331; http://dx.doi.org/10.1128/IAI.01668-13
59. Kari L, Whitmire WM, Olivares-Zavaleta N, Goheen MM, Taylor LD, Carlson JH, Sturdevant GL, Lu C, Bakios LE, Randall LB, et al. A live-attenuated chlamydial vaccine protects against trachoma in nonhuman primates. J Exp Med 2011; 208:2217-23; PMID:21987657; http://dx.doi.org/10.1084/jem.20111266
60. Lei L, Chen J, Hou S, Ding Y, Yang Z, Zeng H, Baseman J, Zhong G. Reduced live organism recovery and lack of hydrosalpinx in mice infected with plasmidfree Chlamydia muridarum. Infect Immun 2014; 82:983-92; PMID:24343644; http://dx.doi.org/10.1128/IAI.01543-13
61. Fata JE, Ho AT, Leco KJ, Moorehead RA, Khokha R. Cellular turnover and extracellular matrix remodeling in female reproductive tissues: functions of metalloproteinases and their inhibitors. Cell Mol Life Sci 2000; 57:77-95; PMID:10949582; http://dx.doi.org/10.1007/s000180050500
62. Ramsey KH, Sigar IM, Schripsema JH, Shaba N, Cohoon KP. Expression of matrix metalloproteinases subsequent to urogenital Chlamydia muridarum infection of mice. Infect Immun 2005; 73:6962-73; PMID:16177376; http://dx.doi.org/10.1128/IAI.73.10.6962-6973.2005
63. Imtiaz MT, Schripsema JH, Sigar IM, Kasimos JN, Ramsey KH. Inhibition of matrix metalloproteinases protects mice from ascending infection and chronic disease manifestations resulting from urogenital Chlamydia muridarum infection. Infect Immun 2006; 74:5513-21; PMID:16988226; http://dx.doi.org/10.1128/IAI.00730-06
64. Ault KA, Kelly KA, Ruther PE, Izzo AA, Izzo LS, Sigar IM, Ramsey KH. Chlamydia trachomatis enhances the expression of matrix metalloproteinases in an in vitro model of the human fallopian tube infection. Am J Obstet Gynecol 2002; 187:1377-83; PMID:12439534; http://dx.doi.org/10.1067/mob.2002.126850
65. Wiesenfeld HC, Heine RP, Krohn MA, Hillier SL, Amortegui AA, Nicolazzo M, Sweet RL. Association between elevated neutrophil defensin levels and endometritis. J Infect Dis 2002; 186:792-7; PMID:12198613; http://dx.doi.org/10.1086/342417
66. Agrawal T, Vats V, Salhan S, Mittal A. Mucosal and peripheral immune responses to chlamydial heat shock proteins in women infected with Chlamydia trachomatis. Clin Exp Immunol 2007; 148:461-8; PMID:17493018; http://dx.doi.org/10.1111/j.1365-2249.2007.03357.x
67. Agrawal T, Vats V, Salhan S, Mittal A. Local markers for prediction of women at higher risk of developing sequelae to Chlamydia trachomatis infection. Am J Reprod Immunol 2007; 57:153-9; PMID:17217370; http://dx.doi.org/10.1111/j.1600-0897.2006.00459.x
68. Agrawal T, Gupta R, Dutta R, Srivastava P, Bhengraj AR, Salhan S, Mittal A. Protective or pathogenic immune response to genital chlamydial infection in women-a possible role of cytokine secretion profile of cervical mucosal cells. Clin Immunol 2009; 130:347-54; PMID:19019735; http://dx.doi.org/10.1016/j.clim.2008.10.004
69. Rank RG, Sanders MM, Patton DL. Increased incidence of oviduct pathology in the guinea pig after repeat vaginal inoculation with the chlamydial agent of guinea pig inclusion conjunctivitis. Sex Transm Dis 1995; 22:48-54; PMID:7709325; http://dx.doi.org/10.1097/00007435-199501000-00008
70. Kelly KA, Walker JC, Jameel SH, Gray HL, Rank RG. Differential regulation of CD4 lymphocyte recruitment between the upper and lower regions of the genital tract during Chlamydia trachomatis infection. Infect Immun 2000; 68:1519-28; PMID:10678969; http://dx.doi.org/10.1128/IAI.68.3.1519-1528.2000
71. Maxion HK, Kelly KA. Chemokine expression patterns differ within anatomically distinct regions of the genital tract during Chlamydia trachomatis infection. Infect Immun 2002; 70:1538-46; PMID:11854242; http://dx.doi.org/10.1128/IAI.70.3.1538-1546.2002
72. Scurlock AM, Frazer LC, Andrews CW Jr., O'Connell CM, Foote IP, Bailey SL, Chandra-Kuntal K, Kolls JK, Darville T. Interleukin-17 contributes to generation of Th1 immunity and neutrophil recruitment during Chlamydia muridarum genital tract infection but is not required for macrophage influx or normal resolution of infection. Infect Immun 2011; 79:1349-62; PMID:21149587; http://dx.doi.org/10.1128/IAI.00984-10
73. Farris CM, Morrison RP. Vaccination against Chlamydia genital infection utilizing the murine C. muridarum model. Infect Immun 2011; 79:986-96; PMID:21078844; http://dx.doi.org/10.1128/IAI. 00881-10
74. Barker CJ, Beagley KW, Hafner LM, Timms P. In silico identification and in vivo analysis of a novel T-cell antigen from Chlamydia, NrdB. Vaccine 2008; 26:1285-96; PMID:18261829; http://dx.doi.org/10.1016/j.vaccine.2007.12.048
75. Karunakaran KP, Rey-Ladino J, Stoynov N, Berg K, Shen C, Jiang X, Gabel BR, Yu H, Foster LJ, Brunham RC. Immunoproteomic discovery of novel T cell antigens from the obligate intracellular pathogen Chlamydia. J Immunol 2008; 180:2459-65; PMID:18250455 http://dx.doi.org/10.4049/jimmunol.180.4.2459
76. Meoni E, Faenzi E, Frigimelica E, Zedda L, Skibinski D, Giovinazzi S, Bonci A, Petracca R, Bartolini E, Galli G, et al. CT043, a protective antigen that induces a CD4C Th1 response during Chlamydia trachomatis infection in mice and humans. Infect Immun 2009; 77:4168-76; PMID:19596772; http://dx.doi.org/10.1128/IAI.00344-09
77. Soriani M, Petit P, Grifantini R, Petracca R, Gancitano G, Frigimelica E, Nardelli F, Garcia C, Spinelli S, Scarabelli G, et al. Exploiting antigenic diversity for vaccine design: the chlamydia ArtJ paradigm. J Biol Chem 2010; 285:30126-38; PMID:20592031; http://dx.doi.org/10.1074/jbc.M110.118513
78. Chaganty BK, Murthy AK, Evani SJ, Li W, Guentzel MN, Chambers JP, Zhong G, Arulanandam BP. Heat denatured enzymatically inactive recombinant chlamydial protease-like activity factor induces robust protective immunity against genital chlamydial challenge. Vaccine 2010; 28:2323-9; PMID:20056182; http:// dx.doi.org/10.1016/j.vaccine.2009.12.064
79. Wang J, Chen L, Chen F, Zhang X, Zhang Y, Baseman J, Perdue S, Yeh IT, Shain R, Holland M, et al. A chlamydial type III-secreted effector protein (Tarp) is predominantly recognized by antibodies from humans infected with Chlamydia trachomatis and induces protective immunity against upper genital tract pathologies in mice. Vaccine 2009; 27:2967-80; PMID:19428908; http://dx. doi.org/10.1016/j.vaccine.2009.02.095
80. Coler RN, Bhatia A, Maisonneuve JF, Probst P, Barth B, Ovendale P, Fang H, Alderson M, Lobet Y,Cohen J, et al. Identification and characterization of novel recombinant vaccine antigens for immunization against genital Chlamydia trachomatis. FEMS Immunol Med Microbiol 2009; 55:258-70; PMID:19281568; http://dx.doi.org/10.1111/j.1574-695X.2008.00527.x
81. Pal S, Theodor I, Peterson EM, de laMaza LM. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge. Infect Immun 2001; 69:6240-7; PMID:11553566; http://dx.doi.org/10.1128/IAI.69.10.6240-6247.2001
82. Berry LJ, Hickey DK, Skelding KA, Bao S, Rendina AM, Hansbro PM, Gockel CM, Beagley KW. Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection. Infect Immun 2004; 72:1019-28; PMID:14742549; http://dx.doi.org/10.1128/IAI.72.2.1019-1028.2004
83. Eko FO, He Q, Brown T, McMillan L, Ifere GO, Ananaba GA, Lyn D, Lubitz W, Kellar KL, Black CM, et al. A novel recombinant multisubunit vaccine against Chlamydia. J Immunol 2004; 173:3375-82; PMID:15322201; http://dx.doi.org/10.4049/jimmunol.173.5.3375
84. Goodall JC, Yeo G, Huang M, Raggiaschi R, Gaston JS. Identification of Chlamydia trachomatis antigens recognized by human CD4C T lymphocytes by screening an expression library. Eur J Immunol 2001; 31:1513-22; PMID:11465108; http://dx.doi .org/10.1002/1521-4141(200105)31:5 ≤ 1513::AIDIMMU1513 ≥3.0.CO;2-U
85. StarnbachMN, LoomisWP, Ovendale P, Regan D, Hess B, Alderson MR, Fling SP. An inclusion membrane protein from Chlamydia trachomatis enters the MHC class I pathway and stimulates a CD8C T cell response. J Immunol 2003; 171:4742-9; PMID:14568950; http://dx.doi.org/10.4049/jimmunol.171.9.4742
86. Hafner LM, Wilson DP, Timms P. Development status and future prospects for a vaccine against Chlamydia trachomatis infection. Vaccine 2014; 32:1563-71; PMID:23973245
87. Yeaman GR, Guyre PM, Fanger MW, Collins JE, White HD, Rathbun W, Orndorff KA, Gonzalez J, Stern JE, Wira CR. Unique CD8C T cell-rich lymphoid aggregates in human uterine endometrium. J Leukoc Biol 1997; 61:427-35; PMID:9103229
88. Mitchell EA, Bergmeier LA, Doyle C, Brookes R, Hussain LA, Wang Y, Lehner T. Homing of mononuclear cells from iliac lymph nodes to the genital and rectal mucosa in non-human primates. Eur J Immunol 1998; 28:3066-74; PMID:9808175; http://dx. doi.org/10.1002/(SICI)1521-4141(199810)28:10≤3066::AID-IMMU3066≥3.0.CO;2-2
89. Johansson M, Lycke NY. Immunology of the human genital tract. Curr Opin Infect Dis 2003; 16:43-9; PMID:12821829; http://dx.doi.org/10.1097/00001432-200302000-00008
90. Morrison SG, Morrison RP. The protective effect of antibody in immunity to murine chlamydial genital tract reinfection is independent of immunoglobulin A. Infect Immun 2005; 73:6183-6; PMID:16113345; http://dx.doi.org/10.1128/IAI.73.9.6183-6186.2005
91. Pal S, Barnhart KM, Wei Q, Abai AM, Peterson EM, de la Maza LM. Vaccination of mice with DNA plasmids coding for the Chlamydia trachomatis major outer membrane protein elicits an immune response but fails to protect against a genital challenge. Vaccine 1999; 17:459-65; PMID:10073724; http://dx.doi. org/10.1016/S0264-410X(98)00219-9
92. Eko FO, Lubitz W, McMillan L, Ramey K, Moore TT, Ananaba GA, Lyn D, Black CM, Igietseme JU. Recombinant Vibrio cholerae ghosts as a delivery vehicle for vaccinating against Chlamydia trachomatis. Vaccine 2003; 21:1694-703; PMID:12639492; http://dx.doi.org/10.1016/S0264-410X(02)00677-1
93. Eko FO, Okenu DN, Singh UP, He Q, Black C, Igietseme JU. Evaluation of a broadly protective Chla-mydia-cholera combination vaccine candidate. Vaccine 2011; 29:3802-10; PMID:21421002; http://dx.doi.org/10.1016/j.vaccine.2011.03.027
94. Dong-Ji Z, Yang X, Shen C, Lu H, Murdin A, Brunham RC. Priming with Chlamydia trachomatis major outer membrane protein (MOMP) DNA followed by MOMP ISCOM boosting enhances protection and is associated with increased immunoglobulin A and Th1 cellular immune responses. Infect Immun 2000; 68:3074-8; PMID:10816446; http://dx.doi.org/10.1128/IAI.68.6.3074-3078.2000
95. Hickey DK, Aldwell FE, Beagley KW. Transcutaneous immunization with a novel lipid-based adjuvant protects against Chlamydia genital and respiratory infections. Vaccine 2009; 27:6217-25; PMID:19698810; http://dx.doi. org/10.1016/j.vaccine.2009.08.001
96. Murthy AK, Chambers JP, Meier PA, Zhong G, Arulanandam BP. Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production. Infect Immun 2007; 75:666-76; PMID:17118987; http://dx.doi.org/10.1128/IAI.01280-06
97. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388:394-7; PMID:9237759; http://dx.doi.org/ 10.1038/41131
98. Berchtold C, Panthel K, Jellbauer S, Köhn B, Roider E, Partilla M, Heesemann J, Endres S, Bourquin C, Rüssmann H. Superior protective immunity against murine listeriosis by combined vaccination with CpG DNA and recombinant Salmonella enterica serovar typhimurium. Infect Immun 2009; 77:5501- 8; PMID:19797070; http://dx.doi.org/10.1128/IAI.00700-09
99. El-Malky M, Shaohong L, Kumagai T, Yabu Y, Noureldin MS, Saudy N, Maruyama H, Ohta N. Protective effect of vaccination with Toxoplasma lysate antigen and CpG as an adjuvant against Toxoplasma gondii in susceptible C57BL/6 mice. Microbiol Immunol 2005; 49:639-46; PMID:16034207; http://dx.doi.org/10.1111/j.1348-0421.2005.tb03656.x
100. Rhee EG, Mendez S, Shah JA, Wu CY, Kirman JR, Turon TN, Davey DF, Davis H, Klinman DM, Coler RN, et al. Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4C and CD8C T cell responses and protection against leishmania major infection. J Exp Med 2002; 195:1565-73; PMID:12070284; http://dx.doi.org/10.1084/jem.20020147
101. Andrew DW, Hafner LM, Beagley KW, Timms P. Partial protection against chlamydial reproductive tract infection by a recombinant major outer membrane protein/CpG/cholera toxin intranasal vaccine in the guinea pig Chlamydia caviae model. J Reprod Immunol 2011; 91:9-16; PMID:21856018; http://dx.doi.org/10.1016/j.jri.2011.06.100
102. Butowski N, Lamborn KR, Lee BL, Prados MD, Cloughesy T, DeAngelis LM, Abrey L, Fink K, Lieberman F, Mehta M, et al. A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. J Neurooncol 2009; 91:183-9; PMID:18850068; http://dx.doi.org/10.1007/s11060-008-9705-3
103. Kim YH, Girardi M, Duvic M, Kuzel T, Link BK, Pinter-Brown L, Rook AH. Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. J Am Acad Dermatol 2010; 63:975-83; PMID:20888065; http://dx.doi.org/10.1016/j.jaad.2009.12.052
104. Sabbatini P, Tsuji T, Ferran L, Ritter E, Sedrak C, Tuballes K, Jungbluth AA, Ritter G, Aghajanian C, Bell-McGuinn K, et al. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res 2012; 18:6497-508; PMID:23032745; http://dx.doi.org/10.1158/1078-0432.CCR-12-2189
105. Garçon N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007; 6:723-39; PMID:17931153; http://dx.doi.org/10.1586/14760584.6.5.723
106. Su H, Messer R, Whitmire W, Fischer E, Portis JC, Caldwell HD. Vaccination against chlamydial genital tract infection after immunization with dendritic cells pulsed ex vivo with nonviable Chlamydiae. J Exp Med 1998; 188:809-18; PMID:9730883; http://dx.doi.org/10.1084/jem.188.5.809
107. Steinman RM, Pope M. Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest 2002; 109:1519-26; PMID:12070296; http://dx.doi.org/10.1172/JCI0215962
108. Parr MB, Kepple L, Parr EL. Langerhans cells phagocytose vaginal epithelial cells undergoing apoptosis during the murine estrous cycle. Biol Reprod 1991; 45:252-60; PMID:1786290; http://dx.doi.org/10.1095/biolreprod45.2.252
109. Agrawal T, Vats V, Wallace PK, Singh A, Salhan S, Mittal A. Recruitment of myeloid and plasmacytoid dendritic cells in cervical mucosa during Chlamydia trachomatis infection. Clin Microbiol Infect 2009; 15:50-9; PMID:19046168; http://dx.doi.org/10.1111/j.1469-0691.2008.02113.x
110. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001; 1:135-45; PMID:11905821; http://dx.doi.org/10.1038/35100529
111. Dudziak D, Kamphorst AO, Heidkamp GF, Buchholz VR, Trumpfheller C, Yamazaki S, Cheong C, Liu K, Lee HW, Park CG, et al. Differential antigen processing by dendritic cell subsets in vivo. Science 2007; 315:107-11; PMID:17204652; http://dx.doi.org/10.1126/science.1136080
112. Bozzacco L, Trumpfheller C, Huang Y, Longhi MP, Shimeliovich I, Schauer JD, Park CG, Steinman RM. HIV gag protein is efficiently cross-presented when targeted with an antibody towards the DEC-205 receptor in Flt3 ligand-mobilized murine DC. Eur J Immunol 2010; 40:36-46; PMID:19830741; http://dx.doi.org/10.1002/eji.200939748
113. Mahnke K, Qian Y, Fondel S, Brueck J, Becker C, Enk AH. Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice. Cancer Res 2005; 65:7007-12; PMID:16061687; http://dx.doi.org/10.1158/0008-5472.CAN-05-0938
114. Trumpfheller C, Finke JS, López CB, Moran TM, Moltedo B, Soares H, Huang Y, Schlesinger SJ, Park CG, Nussenzweig MC, et al. Intensified and protective CD4C T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine. J Exp Med 2006; 203:607-17; PMID:16505141; http://dx. doi.org/10.1084/jem.20052005
115. Matos I, Mizenina O, Lubkin A, Steinman RM, Idoyaga J. Targeting Leishmania major Antigens to Dendritic Cells In Vivo Induces Protective Immunity. PLoS One 2013; 8:e67453; PMID:23840706; http://dx.doi.org/10.1371/journal.pone.0067453
116. Idoyaga J, Lubkin A, Fiorese C, Lahoud MH, Caminschi I, Huang Y, Rodriguez A, Clausen BE, Park CG, Trumpfheller C, et al. Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A. Proc Natl Acad Sci U S A 2011; 108:2384-9; PMID:21262813; http://dx.doi.org/10.1073/pnas.1019547108
117. Caminschi I, Proietto AI, Ahmet F, Kitsoulis S, Shin Teh J, Lo JC, Rizzitelli A, Wu L, Vremec D, van Dommelen SL, et al. The dendritic cell subtyperestricted C-type lectin Clec9A is a target for vaccine enhancement. Blood 2008; 112:3264-73; PMID:18669894; http://dx.doi.org/10.1182/blood-2008-05-155176
118. Birkholz K, Schwenkert M, Kellner C, Gross S, Fey G, Schuler-Thurner B, Schuler G, Schaft N, D örrie J. Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation. Blood 2010; 116:2277-85; PMID:20566893; http://dx.doi.org/10.1182/blood-2010-02-268425
119. Meyer-Wentrup F, Benitez-Ribas D, Tacken PJ, Punt CJ, Figdor CG, de Vries IJ, Adema GJ. Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-alpha production. Blood 2008; 111:4245-53; PMID:18258799; http://dx.doi.org/10.1182/blood-2007-03-081398
120. Svajger U, Anderluh M, Jeras M, Obermajer N. Ctype lectin DC-SIGN: an adhesion, signalling and antigen-uptake molecule that guides dendritic cells in immunity. Cell Signal 2010; 22:1397-405; PMID:20363321; http://dx.doi.org/10.1016/j.cellsig.2010.03.018
121. Pereira CF, Torensma R, Hebeda K, Kretz-Rommel A, Faas SJ, Figdor CG, Adema GJ. In vivo targeting of DC-SIGN-positive antigen-presenting cells in a nonhuman primate model. J Immunother 2007; 30:705-14; PMID:17893563; http://dx.doi.org/10.1097/CJI.0b013e31812e6256
122. + T-cell-mediated protective immunity. Eur J Immunol 2013; 43:2543-53; PMID:23784881; http://dx.doi.org/10.1002/eji.201343429
123. Sun HX, Xie Y, Ye YP. ISCOMs and ISCOMATRIX. Vaccine 2009; 27:4388-401; PMID:19450632; http://dx.doi.org/10.1016/j.vaccine.2009.05.032
124. Steinman RM. Dendritic cells in vivo: a key target for a new vaccine science. Immunity 2008; 29:319-24; PMID:18799140; http://dx.doi.org/10.1016/j.immuni.2008.08.001